Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1034Neoplasms 815Carcinoma, Non-Small-Cell Lung 799Prostatic Neoplasms 621Colorectal Neoplasms 529Lung Neoplasms 486Neoplasm Metastasis 434Multiple Myeloma 395Leukemia, Myeloid, Acute 391Ovarian Neoplasms 334Pancreatic Neoplasms 316Melanoma 297Squamous Cell Carcinoma of Head and Neck 268Recurrence 256Carcinoma, Hepatocellular 250Glioblastoma 238Brain Neoplasms 237Triple Negative Breast Neoplasms 213Carcinoma, Renal Cell 209Head and Neck Neoplasms 208Precursor Cell Lymphoblastic Leukemia-Lymphoma 201Lymphoma 201Stomach Neoplasms 197Endometrial Neoplasms 189Uterine Cervical Neoplasms 185Lymphoma, Non-Hodgkin 180Glioma 180Sarcoma 179Lymphoma, Large B-Cell, Diffuse 167Hematologic Neoplasms 162

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Allogeneic Stem Cell Transplantation × 90 days × Clear all
NCT06297629 2026-05-15

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡